No Data
Zhitong Hong Kong shareholder equity disclosure | November 5
Hong Kong Stock Shareholder Equity Disclosure | November 5th
CHANGMAO BIO: INTERIM REPORT 2024
CITIC Securities: How to look ahead to the future of the csi sws food & beverage index and alcoholic beverages sector as more than half of the interim report period has passed?
Citic Sec released a research report stating that in Q2, the light meal chain industry continued the trend of weak demand, with pressure on store efficiency and expansion.
Changmao Bio (00954.HK) had a mid-year sales revenue of approximately 0.314 billion yuan, a year-on-year increase of about 5.8%.
Changmao Bio (00954.HK) announced that for the six months ended June 30, 2024, the group's sales revenue was RMB 313,802,000, an increase of about 5.8% from RMB 296,608,000 in the same period last year; the net loss attributable to shareholders of the company was approximately RMB 18,786,000. The net income attributable to shareholders of the company in the same period last year was approximately RMB 4,157,000.
Changmao Bio (00954) announced its interim results and the shareholders' losses amounted to 18.786 million yuan, a year-on-year loss of profit.
Changmao Bio (00954) announced its mid-term performance for 2024, with revenue of about 0.314 billion yuan, a year-on-year increase of about 5.8%...
Changmao Bio (00954.HK) recorded a loss of 18.786 million yuan in the first half of the year according to its performance report.
Changmao Bio (00954.HK) announced its interim performance as of the end of June this year, with revenue of CNY 0.314 billion, a year-on-year increase of 5.8%. The company suffered a net loss of CNY 18.786 million, compared to a profit of CNY 4.157 million in the same period last year, with a loss per share of 3.5 cents. No dividends will be distributed.
No Data
No Data